Monthly Archives: May 2019

San Francisco-Based Dr. Mike M. Chen, DMD, DICOI Is Latest To Join The G4 By Golpa Implants Solution National Affiliate Network

A Leading Practitioner, Teacher and Lecturer, Dr. Chen Adds Proprietary G4 Implants Solution Diagnosis and Aftercare Services To His San Francisco Practice

SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 / Dr. Mike Chen, DMD, DICOI, a leading dental practitioner based in Northern California, has become the newest prominent dentist to join the fast-growing G4
by Golpa Dental implants Solution national affiliates network.

Headquartered in San Jose, Dr. Chen is a renowned practitioner, overseeing dental care, diagnosis, treatment and procedures for nearly three decades. Recognized as among the most innovative dentists in California, Dr. Chen is a seasoned trainer and advisor to clinical professionals and students in implant dentistry and a noted authority on current principles, methods and procedures for the delivery of medical evaluation, diagnosis and treatment.

The G4 by Golpa Implants Solution Affiliates Network provides consumers with access to the exclusive G4 Precision Implant Dentistry, perfected by renowned dentist Dr. Mike Golpa (www.g4bygolpa.com) after years – and over 6,000 dental implant surgeries. G4 network dental affiliates receive advanced training by Dr. Golpa in the diagnosis and aftercare of the G4 Implant Solution. Patients have the convenience of accessing a local dentist within the G4 affiliates network to arrange for the exclusive G4 dental implant procedure and receive comprehensive after-treatment care.

“Dr. Golpa has developed a truly state-of-the-art, superior procedure in the ever-growing area of dental implants. As an implants practitioner, I am excited to become part of the G4 network and bring this remarkable implants solution to patients throughout Northern California,” said Dr. Chen.

“We are extremely pleased to welcome Dr. Mike Chen to the G4 Implants Solution affiliates network. Dr. Chen is a passionate advocate for best practices in dental care and is highly regarded by patients for his steadfast commitment to proactive dental hygiene, self-care and maintenance. An organization is best defined by the company it keeps – and having Dr. Chen as a member of G4 underscores the innovativeness and effectiveness of our Implants Solution,” said Dr. Golpa.

About the G4 by Golpa Implant Solution Affiliates Network:

Dr. Mike Golpa’s G4 Implant Solution is practiced in regions across the US by top dentists fully trained in the G4 implant procedure. Dr. Golpa’s G4 Implants Solution has ‘broken the mold’ in providing advanced dental implants technologies, introducing a treatment that delivers a permanent bridge with titanium framework in just one visit. The G4 Implants procedure encompasses proprietary all-digital protocols and next generation milling technologies developed by Dr. Golpa that are changing the cosmetic dentistry landscape. In addition to the continuing expansion of G4 Implant Solutions surgery centers and growing number of dentists adopting the G4 technology, the popularity and proven effectiveness of Dr. Golpa’s procedure has resulted in the government’s approval to offer Medicare support for G4 dental implant patients.

CONTACT:

Steve Syatt / SSA Public Relations
Steve@ssapr.com / (818) 222-4000

SOURCE: Dr. Mike Golpa

ReleaseID: 547185

NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference

FT. MYERS, FL / ACCESSWIRE / May 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be presenting at the 39th Annual William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 10:40am CT in Chicago, IL.

The presentation will be webcast live and accessible online via the investors section of the Company’s website, www.neogenomics.com. A replay of the webcast will be archived for 90 days following the presentation.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit http://www.neogenomics.com/.

Forward Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the information set forth in the “Full-Year 2019 Financial Outlook.” These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company’s ability to continue gaining new customers, offer new types of tests, integrate its acquisition of the Genoptix business and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on February 26, 2019, amended by a 10K/A filed with the SEC on May 8, 2019. As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. In addition, it is the Company’s practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

Forward-looking statements represent the Company’s estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company’s estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

For further information, please contact:

NeoGenomics, Inc.
William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
(239)690-4238 (w) (239)284-4314 (m)
bill.bonello@neogenomics.com

SOURCE: NeoGenomics, Inc.

ReleaseID: 547144

DGSE to Present at the 9th Annual LD Micro Invitational

DALLAS, TX / ACCESSWIRE / May 30, 2019 / DGSE Companies, Inc. (NYSE American: DGSE) (“DGSE” or the “Company”), a leading wholesale, retail and recommerce dealer, announced today that it will be presenting at the 9th annual LD Micro Invitational on June 4th. The LD Micro Invitational will take place at the Luxe Sunset Bel Air Hotel, in Los Angeles, and will be attended by over 1,000 individuals.

This press release includes statements that may constitute “forward-looking” statements, including statements regarding the potential future growth, expansion and the success of business strategies. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, market conditions and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release except as required by law.

CONTACT:

DGSE Companies, Inc.
Corporate Office
13022 Preston Rd, Dallas, TX 75240
972-587-4049
investorrelations@dgse.com

SOURCE: DGSE Companies, Inc.

ReleaseID: 547191

Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference

REDWOOD CITY, CA / ACCESSWIRE / May 30, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the company’s Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which is taking place this week in New Orleans.

Key opinion leaders in the fields of interventional cardiology, vascular surgery and interventional radiology highlighted Avinger’s Lumivascular technology in the following sessions:

Dr. Warren Swee, an interventional radiologist from CLI Vascular Specialists in Delray Beach, Florida, included Avinger’s Pantheris image-guided atherectomy and Ocelot CTO-crossing products in his session, “Optical Coherence Tomography (OCT): Role in Modern Cath Lab”
Dr. Jon George, an interventional cardiologist from Einstein Medical Center in Philadelphia, included Ocelot in his session, “An Overview of Crossing and Re-Entry Tools”
Dr. Jaafer Golzar, an interventional cardiologist from Advocate Medical Group in Chicago and Avinger’s Chief Medical Officer, featured Pantheris SV (Small Vessel) in his session, “OCT Guided Treatment of Infrapopliteal Disease”
Dr. Patrick Muck, a vascular surgeon from Good Samaritan Hospital in Cincinnati, presented data from Avinger’s SCAN clinical study in his session, “Are Intravascular Ultrasound and OCT Being Utilized Enough in Peripheral Interventions?”

Dr. Jaafer Golzar, Avinger’s Chief Medical Officer, commented, “With its comprehensive program and top-notch faculty, NCVH represents an excellent forum for sharing best practices, innovative technologies, and important data relevant to the treatment of PAD. As a faculty member myself, I appreciate the opportunity to update the interventional community on the latest advances in the treatment of complex peripheral arterial disease. I am also very pleased to see my colleagues continue to share how Lumivascular technology positively impacts patient care.”

The NCVH Conference, founded in 1999, provides education in all fields relating to peripheral vascular interventions, with a specific focus on critical limb ischemia and amputation prevention. The conference hosts 1,500+ attendees every year, and includes 24+ live case transmissions, 300+ scientific lectures, and 175+ faculty.

Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger’s proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely on X-ray as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Public Relations Contact:

Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7942
pr@avinger.com

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

SOURCE: Avinger, Inc.

ReleaseID: 547153

Canntab Therapeutics to Present at the 9th Annual LD Micro Invitational

LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab”), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5th at 11:20AM PST / 2:20PM EST. Richard Goldstein, co-founder and Chief Executive Officer of Canntab Therapeutics will be presenting and meeting with investors.

Canntab has filed 13 patents in Canada and the United States and is the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends. We are looking forward to presenting at LD micro as it coincides with the beginning of a larger awareness campaign with the aim of engaging investors and explaining the unique worldwide revenue opportunity that Canntab represents.

“This year’s Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges” stated Chris Lahiji, while waiting in the longest TSA line in history. “Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever growing community.”

The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.

View Canntab Therapeutics profile here: http://www.ldmicro.com/profile/CTABF

Profiles powered by LD Micro – News Compliments of Accesswire

About Canntab Therapeutics Limited

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Jeff Renwick, co-founder and Chief Executive Officer
Phone: +1 289.301.3812
Address: 223 Riviera Dr, Markham, ON L3R 5J6
Email: mailto:Jeff@Canntab.ca

SOURCE: Canntab Therapeutics

ReleaseID: 547187

Local Retailer OnSho Shoes Sells Shoes Online, Gives Back To Local Community

OnSho Shoes is one of the best places to find great prices and impeccable style on fine imported Italian shoes online and best of all, the store is open 24/7!

Houston, United States – May 30, 2019 /PressCable/

Houston, TX: A local online retailer of fine Italian womens shoes online, OnSho Shoes, is one of the best places to find great prices on fine imported shoes. But this retailer also has a special mission. It donates a portion of the proceeds from every sale to local non-profit organizations, ensuring that it gives back to Houston, where it was founded years ago.

“It’s always been very important to us to give back to our local community,” said a spokesperson for OnSho Shoes. “Houston made our company what it is. And even though we sell to people all over America and all over the world, it’s still our home, and we’re trying to do our best to give back and make it a better place.”

OnSho Shoes donates a percentage of its profits to a number of different organizations, including charities that help homeless individuals, veterans, and sexual assault survivors. By giving back, the company ensures that local shoppers can buy high-quality Italian womens shoes online, and feel good about their purchase, knowing that they are supporting both a local business – and local charities.

“There are so many people out there who are struggling, whether it’s a homeless man who needs shelter, a veteran who can’t seem to find a job, or a survivor of domestic violence who is trying to rebuild her family and life,” said a spokesperson for OnSho Shoes. “By donating a portion of our profits to charities helping these folks, we’re doing our part to make Houston a better place.”

Press inquiries can be made at 1-844-44ONSHO.

About OnSho Shoes: OnSho Shoes is an online retailer based in Houston, focusing on selling fine Italian shoes at reasonable prices. With a large inventory and the lowest prices online, this retailer has quickly become a top choice for shoppers all across the country.

Contact Info:
Name: Kristen Jones
Email: Send Email
Organization: OnSho Shoes LLC
Address: 3715 Alba Rd, Houston, Texas 77018, United States
Phone: +1-844-446-6746
Website: https://goo.gl/maps/g7FV1LtvCAK2

Source: PressCable

Release ID: 518276

Arcutis, Inc. to Present at the Jefferies 2019 Global Healthcare Conference

WESTLAKE VILLAGE, CA / ACCESSWIRE / May 30, 2019 / Arcutis, Inc., a privately held immuno-dermatology drug development company addressing significant unmet needs in dermatology, today announced that Frank Watanabe, Arcutis’ President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 9:00 am ET. The Company will host investor meetings during the conference.

About Arcutis – Bioscience, applied to the skin.

Arcutis is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs that address significant unmet medical needs in immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop best-in-class molecules against biologically validated targets, leveraging our industry-leading development expertise to bring to market novel dermatology treatments in less time, at lower cost and with lower risk than other approaches. Arcutis is currently developing two novel compounds (ARQ-151 and ARQ-250) for multiple indications including, psoriasis, atopic dermatitis and eczema. For more information, please visit www.arcutis.com or follow the Company on LinkedIn.

Contact:

John W. Smither
Chief Financial Officer
jsmither@arcutis.com

Investors and Media:

Derek Cole
720.785.4497
derek.cole@IRadvisory.com

SOURCE: Arcutis, Inc.

ReleaseID: 547184

B Communications Reports Financial Results For the First Quarter of 2019

RAMAT GAN, ISRAEL / ACCESSWIRE / May 30, 2019 / B Communications Ltd. (NASDAQ Global Select Market and TASE: BCOM), a holding company with a controlling interest in Israel’s largest telecommunications provider, Bezeq, The Israel Telecommunication Corporation Limited. (TASE: BEZQ), today reported its financial results for the first quarter of 2019.

Recent Developments

On May 19, 2019 we announced that the bondholders of both the Company and Internet Gold-Golden Lines Ltd. (“Internet Gold”) approved in principle Searchlight Capital Partners’ last updated proposal for the purchase of Internet Gold’s shares in B Communications and for additional investment in B Communications as was previously and widely reported on May 14, 2019. The updated investment offer includes a short exclusivity period as detailed in the updated investment proposal.

The final and binding decision regarding the approval of any final agreement according to the updated investment proposal will be made only after the appropriate legal proceedings and necessary legal approvals are obtained, as required. The final and binding approval and voting by the bondholders of both the Company and Internet Gold will be subject to such proceedings.

Searchlight proposal includes the purchase of all the Internet Gold’s holdings in B Communications in consideration for NIS 225 million and a direct investment of NIS 260 million in B Communications. In accordance with the Proposal, upon the Closing, Internet Gold’s shall inject to B Communications an aggregate amount of NIS 345 million (which shall include the consideration payable by Searchlight to Internet Gold) in consideration for shares and debentures B Communications.

The final and binding decision regarding the approval of any final agreement according with the Proposal will be made only after the appropriate legal proceedings and necessary legal approvals, to be held and obtained, as required. The final and binding approval and voting by the bondholders of Internet Gold and B Communications will be subject to such proceedings.

Eventually Searchlight’s updated proposal will result in the injection of NIS 640 million into the Company (compared to only NIS 250 million in the original proposal), consisting approximately of one half of such amount in share capital and the other half in long-term interest-bearing bonds. The Searchlight proposal will also enable the final payment of the Company’s obligations in respect of its Series B bonds as well payments of very substantial amounts (NIS 614 million) on account of its obligations to the existing Series C bondholders (before the allotment of the additional bonds).

The share allotment price in the transaction reflects a discount to the market price of the Company’s shares, but it embodies a premium over the Company’s NAV value based on the share price of Bezeq’s shares during the last 30 trading days. Nevertheless, in the negotiations the Company demanded that all the shareholders be allowed to participate, at least partially, in the share acquisition proposal, and it acted directly to advance this framework. The Company expects that an offer will be made to all of its shareholders to purchase shares for a value of NIS 70 million, with Internet Gold committing to accept its proportionate share (approximately 50%) and Searchlight will purchase any unsubscribed for shares (Such 70 Million are part of the considerations mentioned above).

As previously reported, Bezeq’s assets include a deferred tax asset for carry-forward losses of DBS. Bezeq believes that utilization of this tax asset is probable. While discussing the prospectus, the ISA has asked for clarifications on this matter, and this matter is still being discussed.

On February 14, 2019, Bezeq petitioned the Supreme Court to cancel the structural separation in the Bezeq Group immediately. The Ministry was supposed to respond by May 30, 2019 but on May 28, 2019, it asked for an extension to respond until July 30, 2019. Bezeq is opposed to this extension.

Ami Barlev, CEO of B Communications:

Over the past few weeks, the Company’s management has continued to make intensive efforts to promote alternatives and transactions that will enable a significant capital injection into the Company.

The board of directors considers itself obligated to act to protect the interests of all the Company’s stakeholders, including the Company’s ability to meet its obligations and to safeguard the interests of its creditors. Accordingly, the Company’s management has made intensive efforts to advance a quality proposal and financial solution for the Company.

The board of directors of the Company is of the opinion that Searchlight’s proposal strikes a proper balance between the interests of all the relevant parties, and provides an appropriate solution also considering the other alternatives available to the Company.

The Company’s board of directors intends to continue to act for the benefit of all the Company’s stakeholders. Numerous hurdles still remain ahead in advancing and concluding the transaction itself, including receiving the approvals required by law. The Company believes that if the deal is not completed we shall still retain several options for solving our financial situation.

Regarding Bezeq:

In the first quarter of 2019, the Bezeq Group reduced its net debt by NIS 400 million compared with the corresponding quarter last year. It is important to note the vote of confidence Bezeq received from the Israeli rating agencies, Maalot and Midroog, who recently confirmed the AA rating for the Bezeq Group’s debt. Bezeq intends to continue to maintain the financial strength of the Bezeq Group, among others, by raising new debt that will replace part of the existing debt with longer durations, while continuing to strive towards decreasing overall net debt.

During the quarter, all of the Bezeq Group companies focused on a wide range of streamlining processes aimed at adapting expenses to restrictive regulations, intense market competition and emerging revenue trends. These activities were carried out consistently and continuously at all levels of operations with a long-term view. Technological innovation alongside changes in consumer preferences are impacting the global telecommunications market. Meanwhile, competition in the local market is as intense as ever, and regulatory processes that should have been implemented long ago hinder Bezeq’s ability to compete fairly in the market and deprives consumers of the best possible product offerings. All these factors intensify Bezeq need to capitalize on Bezeq infrastructure and technological advantages in order to improve and diversify the services Bezeq provide to its customers while making the Group more efficient and flexible.

The number of employees in all of the Bezeq Group companies decreased during the first quarter. Results of this process will become more apparent in the coming quarters, along with benefits of additional efficiency measures. At the same time, the Bezeq Group have developed new fields of activity in each of the Bezeq Group companies, while preparing the basis for the next generation of telecommunications services.

B Communications’ Unconsolidated Financial Liabilities and Liquidity

As of March 31, 2019, B Communications’ unconsolidated liquidity balances (comprised of cash and cash equivalents, short term investments and funds deposited in a pledged account) totaled NIS 708 million ($195 million) and its financial liabilities totaled NIS 2.49 billion ($686 million), including NIS 2.26 billion ($622 million) of Series C Debentures and NIS 233 million ($64 million) of Series B Debentures (including accrued interest and unamortized premiums, discounts and debt issuance costs for both series). All of the debt is now classified as currently due.

(In millions)

March 31,

March 31,

March 31,

December 31,

2018

2019

2019

2018

NIS

NIS

US$

NIS

Financial liabilities

Series B debentures

226

233

64

229

Series C debentures

2,257

2,259

622

2,238

Total financial liabilities

2,483

2,492

686

2,467

Liquidity

Cash and short-term investments

467

665

183

546

Pledged account (*)

40

43

12

43

Total liquidity

507

708

195

589

Net debt

1,976

1,784

491

1,878

*Pledged for the benefit of the holders of the Series C Debentures. Pursuant to the indenture for the Series C Debentures, the account is required to include sufficient funds to meet the next interest payment payable to the holders of those debentures.

B Communications First Quarter Unconsolidated Sources and Uses

(In millions)

NIS

US$

Net debt as of December 31, 2018

1,878

517

Financing expenses, net

18

5

Issuance of shares

(117
)

(32
)

Operating expenses

5

1

Net debt as of March 31, 2019

1,784

491

Recent private placement: On January 20, 2019, the Company completed a private placement of 7,385,600 of its ordinary shares, NIS 0.1 par value, to certain institutional, “qualified” and private investors in Israel. The Company’s gross proceeds from the offering was approximately NIS 118 million, based on a price of NIS 16 per share.

Bezeq’s dividend distribution policy: On March 6, 2018, Bezeq’s Board of Directors decided to revise Bezeq’s dividend distribution policy, whereby commencing with Bezeq’s May 2018 distribution it will distribute on a semi-annual basis to its shareholders, a dividend equal to 70% of Bezeq’s semi-annual net profit based on its consolidated financial statements.

On March 27, 2019, Bezeq’s Board of Directors resolved to cancel the Company’s dividend distribution policy, which was updated on March 6, 2018. The decision was made due to the impossibility of distributing a dividend as a result of the expected failure to meet the “profit test” in the next two years. Accordingly, Bezeq’s Board of Directors decided that it would not be appropriate to maintain a dividend policy when in practice it is not effective.

The cancellation of Bezeq’s dividend policy will not prevent Bezeq’s Board of Directors from examining from time to time the distribution of dividends to its shareholders, taking into consideration, among other factors, the provisions of the law, the state of its business and capital structure, and the need to maintain a balance between ensuring its financial strength and stability and the continued creation of value to its shareholders, all of which are subject to the approval of the general meeting of shareholders of Bezeq with respect to each specific distribution, as prescribed in the Bezeq’s Articles of Association.

B Communications First Quarter Consolidated Financial Results

B Communications’ consolidated revenues for the first quarter of 2019 totaled NIS 2.26 billion ($623 million), a 4.4% decrease from NIS 2.36 billion reported in the first quarter of 2018. For both the current and the prior year periods, B Communications’ consolidated revenues consisted entirely of Bezeq’s revenues.

B Communications’ consolidated operating profit for the first quarter of 2019 totaled NIS 443 million ($122 million), a 6.7% increase from 415 NIS million reported in the first quarter of 2018.

B Communications’ consolidated net profit for the first quarter of 2019 totaled NIS 229 million ($63 million), a 17.4% increase from NIS 195 million reported in the first quarter of 2018.

B Communications’ net profit attributable to shareholders for the first quarter of 2019 was NIS 44 million ($12 million), a 57.1% increase from NIS 28 million reported in the first quarter of 2018.

B Communications First Quarter Unconsolidated Financial Results

(In millions)

Three months ended March 31,

Year ended December 31,

2018

2019

2019

2018

NIS

NIS

US$

NIS

Financing expenses, net

(28
)

(18
)

(5
)

(96
)

Operating expenses

(3
)

(5
)

(1
)

(18
)

PPA amortization, net

(9
)

(12
)

(3
)

(634
)

Interest in Bezeq’s net profit

68

79

22

(281
)

Net profit (loss)

28

44

13

(1,029
)

As of March 31, 2019, B Communications held approximately 26.34% of Bezeq’s outstanding shares. B Communications’ interest in Bezeq’s net profit for the first quarter of 2019 totaled NIS 79 million ($22 million), compared with net profit of NIS 68 million reported in the first quarter of 2018.

During the first quarter of 2019, B Communications recorded net amortization expenses related to its Bezeq purchase price allocation (“Bezeq PPA”) of NIS 12 million ($3 million). From April 14, 2010, the date of the acquisition of its interest in Bezeq, until March 31, 2019, B Communications has amortized approximately 82% of the total Bezeq PPA. The Bezeq PPA amortization expense is a non-cash expense that is subject to adjustment.

B Communications’ unconsolidated net financial expenses for the first quarter of 2019 totaled NIS 18 million ($5 million) compared with net financial expenses of NIS 28 million in the first quarter of 2018. Net financial expenses for the first quarter of 2019 included NIS 26 million ($7 million) of financial expenses related to the Company’s Series B and C debentures. Those expenses were partially offset by a financial profit of NIS 8 million ($2 million) generated by short term investments.

B Communications’ unconsolidated net profit for the first quarter of 2019 was NIS 44 million ($13 million) compared with net profit of NIS 28 million reported in the first quarter of 2018.

Bezeq Group Results (Consolidated)

To provide further insight into its results, the Company is providing the following summary of the consolidated financial report of the Bezeq Group for the quarter ended March 31, 2019. For a full discussion of Bezeq’s results for the quarter ended March 31, 2019, please refer to its website: http://ir.bezeq.co.il.

Bezeq Group (consolidated)

Q1-2019

Q1-2018

% change

(NIS millions)

Revenues

2,256

2,361

(4.4
%)

Operating profit

511

462

10.6
%

Operating margin

22.7
%

19.6
%

Net profit

300

260

15.4
%

EBITDA

977

987

(1.0
%)

EBITDA margin

43.3
%

41.8
%

Diluted EPS (NIS)

0.11

0.09

22.2
%

Cash flow from operating activities

765

909

(15.8
%)

Payments for investments

373

368

1.4
%

Free cash flow 1

316

423

(25.3
%)

Total debt

11,156

12,156

(8.2
%)

Net debt

8,544

8,940

(4.4
%)

EBITDA (trailing twelve months)

1,631

3,818

(57.3
%)

Adjusted EBITDA (trailing twelve months)

3,465

3,811

(9.1
%)

Net debt / Adjusted EBITDA (end of period) 2

2.47

2.35

1 Free cash flow is defined as cash flow from operating activities less net payments for investments.
2 Adjusted EBITDA in this calculation refers to the trailing twelve months.

Revenues of the Bezeq Group in the first quarter of 2019 were NIS 2.26 billion ($621 million) compared to NIS 2.36 billion in the corresponding quarter of 2018, a decrease of 4.4%. The decrease was due to lower revenues in all the Bezeq Group segments.

Salary expenses of the Bezeq Group in the first quarter of 2019 were NIS 492 million ($135 million) compared to NIS 510 million in the corresponding quarter of 2018, a decrease of 3.5%.

Operating expenses of the Bezeq Group in the first quarter of 2019 were NIS 812 million ($223 million) compared to NIS 841 million in the corresponding quarter of 2018, a decrease of 3.4%. The decrease was primarily due to lower expenses in Pelephone and DBS.

Other operating income, net in the first quarter of 2019 was NIS 25 million ($7 million) compared to operating expenses of NIS 23 million in the same quarter of 2018. Other operating income was impacted by the recording of capital gains from the sale of real estate of NIS 44 million and the cancellation of a provision for the early retirement of employees of NIS 25 million in Bezeq Fixed-Line, which gains were partially offset by a provision of NIS 45 million for the early retirement of DBS employees.

Depreciation and amortization expenses of the Bezeq Group in the first quarter of 2019 were NIS 466 million ($128 million) compared to NIS 525 million in the corresponding quarter of 2018, a decrease of 11.2%. The decrease in depreciation expenses was primarily due to the impairment of depreciable assets and surplus acquisition costs in DBS in the fourth quarter of 2018. The decrease was partially offset by the ongoing impairment losses in DBS in the first quarter of 2019.

Operating profit of the Bezeq Group in the first quarter of 2019 was NIS 511 million ($140 million) compared to NIS 462 million in the corresponding quarter of 2018, an increase of 10.6%.

Financing expenses, net of the Bezeq Group in the first quarter of 2019 amounted to NIS 99 million ($27 million) compared to NIS 108 million in the corresponding quarter of 2018, a decrease of 8.33%. The decrease in financing expenses in 2019 was primarily due to the decrease in financing expenses in Bezeq Fixed-Line.

Tax expenses of the Bezeq Group in the first quarter of 2019 were NIS 112 million ($31 million) compared to NIS 93 million in the corresponding quarter of 2018, an increase of 20.43%.

Net profit of the Bezeq Group in the first quarter of 2019 was NIS 300 million ($82 million) compared to NIS 260 million in the corresponding quarter of 2018, an increase of 15.38%.

EBITDA of the Bezeq Group in the first quarter of 2019 was NIS 977 million ($269 million) (EBITDA margin of 43.3%) compared to NIS 987 billion (EBITDA margin of 41.8%) in the corresponding quarter of 2018, a decrease of 1%.

Adjusted EBITDA (trailing twelve months) of the Bezeq Group as of March 31, 2019, was NIS 3.47 billion ($955 million) compared to NIS 3.81 billion as of March 31, 2018.

Cash flow from operating activities of the Bezeq Group in the first quarter of 2019 was NIS 765 million ($210 million) compared to NIS 909 million in the corresponding quarter of 2018, a decrease of 15.8%. The decrease in cash flow from operating activities was primarily due to changes in working capital.

Payments for investments (Capex) of the Bezeq Group in the first quarter of 2019 was NIS 373 million ($102 million) compared to NIS 368 million in the corresponding quarter of 2018, an increase of 1.4%.

Free cash flow of the Bezeq Group in the first quarter of 2019 was NIS 316 million ($87 million) compared to NIS 423 million in the corresponding quarter of 2018, a decrease of 25.3%. The decrease in free cash flow was primarily due to the aforementioned decrease in cash flow from operating activities.

Total debt of the Bezeq Group as of March 31, 2019 was NIS 11.15 billion ($3.07 billion) compared to NIS 12.2 billion as of March 31, 2018.

Net debt of the Bezeq Group was NIS 8.54 billion ($2.35 billion) as of March 31, 2019 compared to NIS 8.94 billion as of March 31, 2018.

Net debt to adjusted EBITDA (trailing twelve months) ratio of the Bezeq Group as of March 31, 2019, was 2.47 compared to 2.35 as of March 31, 2018.

Notes:

Convenience translation to U.S Dollars

Unless noted specifically otherwise, the dollar denominated figures were converted to US$ using a convenience translation based on the New Israeli Shekel (NIS)/US$ exchange rate of NIS 3.63 = US$ 1 as published by the Bank of Israel for March 31, 2019.

Reporting Principles and Accounting Policy

Presentation of impairment losses

An impairment loss arising from a non-recurring adjustment of forecasts for the coming years is classified as other operating expenses in the statement of income. On the other hand, an impairment loss arising from the continuous adjustment of non-current assets of the Group companies to their fair value, less disposal costs (arising due to the expected negative cash flow and negative operating value of those companies) is classified under the same items as the current expenses for these assets. This classification is more consistent with the presentation method based on the nature of the expense and is more suitable for understanding the Group’s business.

Accordingly, as from the first quarter of 2019, impairment of the broadcasting rights in DBS and Walla! are presented under “operating and general expenses”, while impairment of fixed assets and intangible assets are presented under “depreciation, amortization and impairment” in the statement of income.

Use of non-IFRS financial measures

We and the Bezeq Group’s management regularly use supplemental non-IFRS financial measures internally to understand, manage and evaluate its business and make operating decisions. The following non-IFRS measures are provided in the press release and accompanying supplemental information because management believes these measurements are useful for investors and financial institutions to analyze and compare companies on the basis of operating performance:

EBITDA – defined as net profit plus net interest expense, provision for income taxes, depreciation and amortization;

EBITDA trailing twelve months – defined as net profit plus net interest expense, provision for income taxes, depreciation and amortization during last twelve months;

Net debt – defined as long and short-term liabilities minus cash and cash equivalents and short-term investments; and

Net debt to adjusted EBITDA ratio – defined as net debt divided by the trailing twelve months adjusted EBITDA.

Free Cash Flow – defined as cash from operating activities less cash for the purchase/sale of property, plant and equipment, and intangible assets, net and lease payments.

These non-IFRS financial measures may differ materially from the non-IFRS financial measures used by other companies.

We present the Bezeq Group’s EBITDA as a supplemental performance measure because we believe that it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structure, tax positions (such as the impact of changes in effective tax rates or net operating losses) and the age of, and depreciation expenses associated with, fixed assets (affecting relative depreciation expense).

EBITDA should not be considered in isolation or as a substitute for net profit or other statement of operations or cash flow data prepared in accordance with IFRS as a measure of profitability or liquidity. EBITDA does not take into account our debt service requirements and other commitments, including capital expenditures, and, accordingly, is not necessarily indicative of amounts that may be available for discretionary uses. In addition, EBITDA, as presented in this press release, may not be comparable to similarly titled measures reported by other companies due to differences in the way that these measures are calculated.

Management of Bezeq believes that free cash flow is an important measure of its liquidity as well as its ability to service long-term debt, fund future growth and to provide a return to shareholders. We also believe this free cash flow definition does not have any material limitations. Free cash flow is a financial index which is not based on IFRS. Free cash flow is defined as cash from operating activities less cash for the purchase/sale of property, plant and equipment, and intangible assets, net. Bezeq also uses the net debt and net debt to EBITDA trailing twelve months ratio to analyze its financial capacity for further leverage and in analyzing the company’s business and financial condition. Net debt reflects long and short-term liabilities minus cash and cash equivalents and investments.

Reconciliations between the Bezeq Group’s results on an IFRS and non-IFRS basis with respect to these non-IFRS measurements are provided in tables immediately following the Company’s consolidated results. The non-IFRS financial measures are not meant to be considered in isolation or as a substitute for comparable IFRS measures and should be read only in conjunction with its consolidated financial statements prepared in accordance with IFRS.

About B Communications Ltd.

B Communications is a holding company with the controlling interest in Israel’s largest telecommunications provider, Bezeq. For more information please visit the following Internet sites:

www.igld.com
www.bcommunications.co.il
www.ir.bezeq.co.il

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, general business conditions in the industry, changes in the regulatory and legal compliance environments, the failure to manage growth and other risks detailed from time to time in B Communications’ filings with the Securities Exchange Commission. These documents contain and identify other important factors that could cause actual results to differ materially from those contained in our projections or forward-looking statements. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We undertake no obligation to update publicly or revise any forward-looking statement.

For further information, please contact:

Yuval Snir – IR Manager
Yuval@igld.com / Tel: +972-3-924-0000

Hadas Friedman – Investor Relations
Hadas@km-ir.co.il / Tel: +972-3-516-7620

B Communications Ltd.

Consolidated Statements of Financial Position as at

(In millions)

March 31,

March 31,

March 31,

December 31,

2018

2019

2019

2018

NIS

NIS

US$

NIS

(Unaudited)

(Unaudited)

(Unaudited)

(Audited)

Current Assets

Cash and cash equivalents

1,975

1,666

459

1,104

Investments

1,748

1,653

455

1,780

Trade receivables

1,827

1,760

485

1,773

Other receivables

306

281

77

269

Related party

25

Inventory

130

102

28

97

Total current assets

6,011

5,462

1,504

5,023

Non-Current Assets

Trade and other receivables

466

511

141

470

Property, plant and equipment

6,922

6,283

1,731

6,313

Intangible assets

5,764

4,203

1,158

4,227

Deferred expenses and investments

606

505

139

509

Broadcasting rights

451

19

60

Rights of use assets

1,417

1,444

398

1,504

Deferred tax assets

1,027

1,193

328

1,205

Investment property

64

18

64

Total non-current assets

16,653

14,272

3,932

14,352

Total assets

22,664

19,734

5,436

19,375

B Communications Ltd.
Consolidated Statements of Financial Position as at (cont’d)
(In millions)

March 31,

March 31,

March 31,

December 31,

2018

2019

2019

2018

NIS

NIS

US$

NIS

(Unaudited)

(Unaudited)

(Unaudited)

(Audited)

Current Liabilities

Bank loans and credit and debentures

1,835

3,993

1,100

3,997

Leases rights liabilities

428

422

116

445

Trade and other payables

1,847

1,881

518

1,702

Current tax liabilities

50

17

5

8

Provisions

103

145

40

175

Employee benefits

286

500

138

581

Total current liabilities

4,549

6,958

1,917

6,908

Non-Current Liabilities

Bank loans and debentures

12,776

9,618

2,650

9,637

Leases rights liabilities

1,006

1,061

292

1,106

Employee benefits

272

482

132

445

Other liabilities

258

168

46

175

Provisions

39

39

11

38

Deferred tax liabilities

461

286

79

302

Total non-current liabilities

14,812

11,654

3,210

11,703

Total liabilities

19,361

18,612

5,127

18,611

Equity

Attributable to shareholders of the Company

1,280

392

108

228

Non-controlling interests

2,023

730

201

536

Total equity

3,303

1,122

309

764

Total liabilities and equity

22,664

19,734

5,436

19,375

B Communications Ltd.
Consolidated Statements of Income for the
(In millions except per share data)

Year ended

Three months ended March 31,

December 31,

2018

2019

2019

2018

NIS

NIS

US$

NIS

(Unaudited)

(Unaudited)

(Unaudited)

(Audited)

Revenues

2,361

2,257

623

9,321

Costs and expenses

Depreciation and amortization

569

505

139

2,387

Salaries

510

495

137

1,995

General and operating expenses

844

814

3,394

Impairment losses

2,294

Other operating expense net

23

635

1,946

1,814

501

10,705

Operating profit (loss)

415

443

(1,384
)

Financing expenses, net

136

117

32

531

Profit (loss) after financing expenses, net

279

326

90

(1,915
)

Share of loss in equity-accounted investee

1

3

Profit (loss) before income tax

278

326

90

(1,918
)

Tax expenses (income)

83

97

27

(59
)

Net profit (loss) for the period

195

229

63

(1,859
)

Profit (loss) attributable to:

Shareholders of the Company

28

44

12

(1,029
)

Non-controlling interests

167

185

51

(830
)

Net profit (loss) for the period

195

229

63

(1,859
)

Earnings (loss) per share

Basic

0.94

1.22

0.34

(34.44
)

Diluted

0.94

1.22

0.34

(34.44
)

Reconciliation for NON-IFRS Measures

EBITDA

The following is a reconciliation of the Bezeq Group’s net profit to EBITDA:

(In millions)

Three-months period ended March 31,

Trailing twelve months ended March 31,

2018

2019

2019

2018

2019

2019

NIS

NIS

US$

NIS

NIS

US$

Net profit (loss)

260

300

83

1,145

(1,026
)

(282
)

Tax expenses (income)

93

112

31

433

99

27

Share of loss (income) in equity- accounted investee

1

4

2

1

Financing expenses, net

108

99

27

424

426

117

Depreciation and amortization

525

466

129

1,812

2,130

587

EBITDA

987

977

270

3,818

1,631

450

Other operating expenses (income)

23

(25
)

(7
)

8

586

161

Impairment losses

87

1,675

461

Effect of adoption of accounting standard IFRS 16

(102
)

(117
)

(32
)

(102
)

(427
)

(118
)

Adjusted EBITDA

908

835

231

3,811

3,465

954

Net Debt

The following table shows the calculation of the Bezeq Group’s net debt:

(In millions)

As at March 31,

2018

2019

2019

NIS

NIS

US$

Short term bank loans and credit and debentures

1,609

1,538

424

Non-current bank loans and debentures

10,547

9,618

2,648

Cash and cash equivalents

(1,826
)

(1,265
)

(348
)

Investments

(1,390
)

(1,347
)

(371
)

Net debt

8,940

8,544

2,353

Net Debt to Trailing Twelve Months EBITDA Ratio

The following table shows the calculation of the Bezeq Group’s net debt to Adjusted EBITDA trailing twelve months ratio:

(In millions)

As at March 31,

2018

2019

2019

NIS

NIS

US$

Net debt

8,940

8,544

2,353

Trailing twelve months Adjusted EBITDA

3,811

3,465

955

Net debt to Adjusted EBITDA ratio

2.35

2.47

2.47

Reconciliation for NON-IFRS Measures

Free Cash Flow

The following table shows the calculation of the Bezeq Group’s free cash flow:

(In millions)

Three-month period ended March 31,

2018

2019

2019

NIS

NIS

US$

Cash flow from operating activities

909

765

210

Purchase of property, plant and equipment

(273
)

(270
)

(74
)

Investment in intangible assets and deferred expenses

(95
)

(103
)

(28
)

Lease payments

(126
)

(117
)

(32
)

Proceeds from the sale of property, plant and equipment

8

41

11

Free cash flow

423

316

87

Designated Disclosure with Respect to the Company’s Projected Cash Flows

In connection with the issuance of our Series C Debentures in September 2016, we undertook to comply with the “hybrid model disclosure requirements” as determined by the Israeli Securities Authority and as described in the prospectus governing our Series C Debentures.

This model provides that in the event certain financial “warning signs” exist, and for as long as they exist, we will be subject to certain disclosure obligations towards the holders of our Series C Debentures.

In March 2019, we announced that because of the write-downs to date the aggregate material decline in the assets and the accounting equity of our company was expected to be in a cumulative range of NIS 700-800 million. Our Board of Directors decided at its meeting held on the evening of March 19, 2019, that because of the foregoing, as well as Including due to the sequence of events of deterioration in the Group, we should enter into a dialogue with the holders of our Debentures in order to examine financial possibilities for strengthening our shareholders’ equity or to obtain adjustments to the current Deeds of Trust governing the Debentures. The Board further determined to withhold payments to its financial creditors until such agreements are finalized. The determination to withhold payments led to significant discussions with our debenture holders who are now being consulted with respect to future actions of our company while we attempt to resolve the current financial predicament.

In examining the existence of warning signs as of March 31, 2019, our board of directors noted that our unconsolidated unaudited cash flow statement for the first quarter of 2019 reflects that we, as expected, had a continuing negative cash flow from operating activities of NIS 5 million. In addition, the Company’s unaudited statements of financial position as of March 31, 2019, reflect that the Company had negative working capital of approximately NIS 1.8 billion as of such date as a result of the classification of the Compan’y long term debt to “short-term”.

On May 19, 2019 we announced that the bondholders of both the Company and Internet Gold-Golden Lines Ltd. (“Internet Gold”) approved in principle Searchlight Capital Partners’ last updated proposal for the purchase of Internet Gold’s shares in B Communications and for additional investment in B Communications as was previously and widely reported on May 14, 2019. The updated investment offer includes a short exclusivity period as detailed in the updated investment proposal.

The final and binding decision regarding the approval of any final agreement according to the updated investment proposal will be made only after the appropriate legal proceedings and necessary legal approvals are obtained, as required. The final and binding approval and voting by the bondholders of both the Company and Internet Gold will be subject to such proceedings.

Searchlight proposal includes the purchase of all the Internet Gold’s holdings in B Communications in consideration for NIS 225 million and a direct investment of NIS 260 million in B Communications. In accordance with the Proposal, upon the Closing, Internet Gold’s shall inject to B Communications an aggregate amount of NIS 345 million (which shall include the consideration payable by Searchlight to Internet Gold) in consideration for shares and debentures B Communications.

The final and binding decision regarding the approval of any final agreement according with the Proposal will be made only after the appropriate legal proceedings and necessary legal approvals, to be held and obtained, as required. The final and binding approval and voting by the bondholders of Internet Gold and B Communications will be subject to such proceedings.

Eventually Searchlight’s updated proposal will result in the injection of NIS 640 million into the Company (compared to only NIS 250 million in the original proposal), consisting approximately of one half of such amount in share capital and the other half in long-term interest-bearing bonds. The Searchlight proposal will also enable the final payment of the Company’s obligations in respect of its Series B bonds as well payments of very substantial amounts (NIS 614 million) on account of its obligations to the existing Series C bondholders (before the allotment of the additional bonds).

The process of acceptance of the said proposal, as well as other alternatives that are examined by the Company from time to time, constitutes a basis for resolving the Company’s financial situation and dealing with the debt arrangement required for execution by the Company.

Disclosure with Respect to the Company’s Requirements Under Series C Debentures

The Company declares with respect to the reporting period as follows:

1. The Company did not record in favor of a third party any lien of any rank whatsoever over its direct or indirect holdings of 691,361,036 shares of Bezeq (the “Bezeq Shares”) including over any of the rights accompanying such shares.

2. The Company did not make any disposition of the Bezeq Shares.

3. The Company did not assume any financial debt (as defined in the Trust Deed of the Series C Debentures) during the reporting period (other than in the framework of the issuance of the Debentures, and its wholly owned subsidiaries, including B Communications (SP1) and B Communications (SP2) did not issue any financial debt whatsoever during the reporting period.

4. As of the reporting date, the Company holds approximately 26.34% of Bezeq’s outstanding shares, directly and through its subsidiary.

5. The equity attributable to the Company’s shareholders (not including non-controlling interests) according to this report amounts to NIS 392 million and represents 13.55% of the Company’s total balance sheet on an unconsolidated basis.

B Communications’ Unconsolidated Statement of Financial position as at

(In millions)

March 31,

March 31,

March 31,

December 31,

2018

2019

2019

2018

NIS

NIS

US$

NIS

Current assets

Cash and cash equivalents

149

401

110

213

Short-term investments

358

306

84

376

Other receivables

2

1

2

Total current assets

507

709

195

591

Non-current assets

Investment in an investee (*)

3,261

2,182

601

2,112

Total assets

3,768

2,891

796

2,703

Current liabilities

Current maturities of debentures

226

2,455

677

2,455

Other payables

33

44

12

20

Total current liabilities

259

2,499

689

2,475

Non-current liabilities

Debentures

2,229

Total liabilities

2,488

2,499

689

2,475

Total equity

1,280

392

107

228

Total liabilities and equity

3,768

2,891

796

2,703

(*) Investment in Bezeq.

SOURCE: B Communications Ltd.

ReleaseID: 547151

A Comprehensive Look at the Dynamic Relationship Between Great White Sharks, Gray Seals and The Commercial Fishermen Caught in the Middle

BREWSTER, MA / ACCESSWIRE / May 30, 2019 / Peter Trull is a world class naturalist and the go-to expert for all things wild on Cape Cod. In this fascinating book, he explores the complexity of cause and effect in a natural ecosystem as three of the ocean’s top predators converge on Cape Cod.

Gregory Skomal, Ph.D.
Senior Marine Fisheries Scientist
MA Marine Fisheries

The Gray Curtain

Discover, through exciting and informative text, and 120 vivid images, the dynamic interrelationship between expanding gray seal populations and great white sharks along the beaches of Cape Cod and the northeast coast. The “Gray Curtain” has come about as a result of geologic and environmental changes, as well as a dramatic increase to over 20,000 Gray Seals that have impacted the area. There are great transformations taking place in the region, and both fishermen and scientists play a role in these dynamic coastal changes. However, they don’t always agree on why the changes have occurred. In the minds of many commercial fishermen, the return of the now-protected gray seal has played a major part. Today however, a new charismatic, apex predator has entered the picture: The Great White Shark. Responsible for several shark attacks on humans in the last few years. This enlightening, intriguing and colorful book brings together the main factors that have created the phenomenon of The Gray Curtain.

https://www.youtube.com/watch?v=pt1717BgVu0

www.petertrull.org

A program/lecture presentation on The Gray Curtain is available upon request for your organization, club or business – Peter Trull.

Peter Trull is at once a keen naturalist, an engaging storyteller, a contemplative author, a brilliant photographer, and a gifted educator. His visual and literary legacies have previously and artfully informed Cape Cod residents and visitors alike about the lives of some of the region’s most iconic species.

Wayne R. Petersen
Massachusetts Audubon Society

Contact:

Peter Trull
508-237-0580
petrull@comcast.net

SOURCE: Peter Trull Books

ReleaseID: 547171

Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California.

Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors.

“This year’s Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges,” stated Chris Lahiji, President at LD Micro. “Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community.”

The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals. View Cannabics Pharmaceuticals’ profile here: http://www.ldmicro.com/profile/CNBX.

Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

LD started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Cannabics Pharmaceuticals

Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.

For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

For more information about Cannabics:

Cannabics Pharmaceuticals Inc.
Phone: +1 (877) 424-2429
info@cannabics.com
http://www.cannabics.com

Related Links
http://www.cannabics.com

SOURCE: Cannabics Pharmaceuticals Inc.

ReleaseID: 547173